The Question

A dental researcher holding a model of a jaw with developing tooth buds, beside a microscope in a laboratory

Humans grow two sets of teeth in a lifetime: the baby teeth that fall out in childhood and the adult teeth that replace them. That has always seemed like a hard biological limit — lose an adult tooth, and your only options are a bridge, an implant, or a denture. But biology hid a surprise. Studies of the jaw show that many people carry the faint beginnings of extra teeth, dormant buds that ordinarily stall and never emerge. The clearest proof comes from a condition called hyperdontia, in which some people simply grow additional teeth beyond the normal count — living evidence that the body retains the instructions to build more.

If the blueprint for a third set of teeth already exists inside us, a natural question follows: could it be switched back on? What has changed is that scientists have identified a specific molecular brake that keeps those extra teeth from forming — and have built a drug to release it. The question is no longer whether spare teeth exist in principle, but whether a medicine can coax them into the mouth safely.

What the Evidence Shows

The work centres on a Japanese team led by Katsu Takahashi, head of dentistry and oral surgery at the Medical Research Institute Kitano Hospital in Osaka, working with the company Toregem BioPharma. His group focused on a protein called USAG-1, which acts as a brake on tooth growth — it suppresses the signals that would otherwise tell buds to develop. Reasoning that removing the brake might release dormant teeth, the researchers created an antibody drug that blocks USAG-1. In animals, the results were striking: in a 2021 study published in Science Advances, blocking USAG-1 rescued tooth development in mice with several genetic forms of congenital tooth agenesis, and the authors concluded that the antibody was "a promising approach for tooth regeneration therapy."

The decisive step came in October 2024, when a Phase I trial of the antibody, called TRG035, began at Kyoto University Hospital. As is standard for a new medicine, it focused on safety: about 30 healthy adult men aged 30 to 64, each missing at least one molar, received the drug or a placebo at rising doses. Toregem says the trial confirmed the drug's safety, although detailed results have not been published. In 2026 the company raised US$5.3 million for the next stage, and Japan's Pharmaceuticals and Medical Devices Agency completed its review of the plan for a Phase II trial in 24 children with severe congenital tooth agenesis — though the study still needed ethics approval before it could begin. The initial therapeutic target is not the general public but people born with congenital tooth agenesis — a condition in which individuals are missing several or many teeth from birth, often causing serious difficulty eating and speaking. If the drug proves safe and effective there, the researchers hope to broaden it toward the far larger group of people who have lost teeth to decay, gum disease, or injury.

"The idea of growing new teeth is every dentist's dream. I've been working on this since I was a graduate student. I was confident I'd be able to make it happen."

— Katsu Takahashi, Medical Research Institute Kitano Hospital, to The Mainichi (via Dental Tribune)

The context makes this genuinely significant. For all its polish, the way modern dentistry replaces a lost tooth has not changed in concept for a very long time: it substitutes an artificial object — a denture that sits on the gums or an implant screwed into the bone — for the real thing. A treatment that regrows a patient's own living tooth, rather than fitting a manufactured replacement, would be a categorical shift, not merely a better version of what already exists.

The plan for a third set of teeth was written into the body long ago. The task now is only to lift the switch that keeps it filed away.

Why This Is Happening

The biological target is unusually well understood. Rather than trying to build a tooth from scratch, the approach works with a mechanism the body already possesses — dormant buds and a known protein brake holding them back. Removing a single brake is a far simpler and more plausible intervention than growing an organ artificially, which is why this line of research has advanced from animals to humans faster than most regenerative medicine.

The unmet need is vast and growing. Tooth loss affects an enormous share of humanity and worsens with an ageing global population. Dentures and implants, though effective, are costly, imperfect, and sometimes poorly tolerated.

Japan's clinical and regulatory environment favours the attempt. Starting with a defined patient group — children and adults born missing teeth — gives the trials a clear, ethically compelling focus and a realistic path through approval before any broader use is considered.


What Could Happen

Approval first for people born missing teeth, then wider use Less likely

Trials confirm the drug is safe and can regrow teeth in people born missing them, and approval follows first for that group in Japan, then gradually elsewhere. Use then begins to extend, cautiously, toward adults who have lost teeth to decay or injury. Dentures and implants do not vanish overnight, but for the first time a genuine biological alternative sits alongside them.

It works, but only for narrow cases by 2040 Possible

The therapy succeeds for congenital tooth agenesis but proves harder to extend to ordinary age-related tooth loss, where the dormant buds may be absent or the biology less cooperative. It becomes a valued treatment for a specific group rather than a replacement for mainstream dentistry, with wider use pushed beyond 2040.

Slow trials, setbacks or failure delay approval past 2040 Most likely

Trials in children take years to show whether new teeth actually grow, funding is tight for a small company, or studies reveal side effects, teeth that grow in the wrong place or shape, or benefits too small to justify approval. Development slows or restarts with a revised approach, and approval slips past 2040. Most experimental medicines meet a fate like this — though the clean animal results and staged trial design improve the odds.

Our Assessment
We assign 30% probability — possible, but unlikely that by 2040, tooth regeneration is an approved medical treatment. We have lowered this forecast from 64%: the drug has passed only a first safety study, its Phase II trial in children had not yet started by late 2026, and most medicines that enter human trials never reach approval. The science is genuinely promising: the biological rationale is sound, the target patients have few alternatives, and an approval for children born missing teeth could come in Japan in the 2030s. The main uncertainties are the ordinary hazards of clinical development — safety, effectiveness, and how far the therapy extends beyond people born missing teeth. This is a real breakthrough in progress, not a certainty; the coming trial results will decide how much of the promise reaches patients, and how soon.

What Can We Do

A patient smiling in a dental chair while a dentist reviews an X-ray of the jaw on a screen

A working tooth-regeneration drug is still years away, and the sensible response is patience paired with attention rather than premature hope.

Keep protecting the teeth you have. Even in the best case, regeneration will arrive gradually and be reserved at first for specific patients. Brushing, flossing, and regular dental care remain by far the most reliable way to keep your natural teeth. No pipeline drug is a reason to neglect the basics that already work.

Follow the trials, not the headlines. This field attracts breathless coverage that outruns the evidence. Watch for peer-reviewed results and official regulatory milestones from the Japanese trials, which give an honest read on progress. Treat any claim of imminent, universal tooth regrowth with healthy scepticism until the data support it.

Support patients born without teeth. The first and clearest beneficiaries are people with congenital tooth agenesis, who often face lifelong difficulty and cost. Backing research and coverage aimed at this group is both the most ethical priority and the route through which the broader therapy is most likely to arrive.

Weigh today's options on today's evidence. If you need a tooth replaced now, decide based on proven implants and dentures, not on a treatment still in trials. Regeneration may transform dentistry within a couple of decades, but present decisions should rest on what is available and reliable today.